Kura Oncology (KURA) Q4 2025 earnings summary

Executive summary

• Komzifti (ziftomenib) launched in 2025 with FDA approval, generating $2.1 million in net product revenue in the final weeks of the year and rapid payer coverage for relapsed/refractory NPM1-mutated AML.

• Strong physician, pharmacist, and payer feedback highlighted efficacy, safety, combinability, and convenience, supporting broader development plans targeting up to 50% of AML patients.

• Komzifti was added to NCCN guidelines as a Category 2A recommendation within a week of submission, reflecting strong clinical endorsement.

• The company is executing a comprehensive development strategy for ziftomenib across the AML continuum and advancing a robust pipeline in solid tumors, with multiple 2026 clinical data milestones expected.

Financial highlights

• Net product revenue from Komzifti sales was $2.1 million in Q4 2025, compared to none in Q4 2024.

• Collaboration revenue from Kyowa Kirin was $15.2 million, down from $53.9 million year-over-year.

• R&D expenses rose to $64.4 million from $52.3 million, driven by ziftomenib combination trials and KOMET-017 enrollment.

• SG&A expenses increased to $39.1 million from $24.1 million, reflecting commercialization investments.

• Net loss widened to $81 million from $19.2 million year-over-year.

• Cash, equivalents, and short-term investments stood at $667.2 million at year-end 2025.

Outlook and guidance

• Collaboration revenue guidance: $45–$55 million in 2026, $90–$110 million in 2027 and 2028.

• Cash and anticipated collaboration payments expected to fund operations into Q4 2027 and support the ziftomenib AML program through topline Phase 3 results in 2028.

• 2026 priorities include accelerating Komzifti uptake, delivering quarter-over-quarter revenue growth, and advancing frontline and combination strategies, with multiple clinical milestones anticipated.